All In Biotech

Drug Trial Radar · NCT04781816

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

Randomized, Double-blind, Placebo Controlled, Proof of Concept Study Assessing the Efficacy and Safety of the RIPK1-inhibitor SAR443122 in Patients With Moderate to Severe Subacute or Discoid/Chronic Cutaneous Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Apr 1, 2021

Primary completion

May 25, 2023

Study completion Jun 26, 2023

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: * Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE) Secondary Objectives: * Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity) * Assess the effect of SAR443122 on CLE induced itch and overall pain * Assess the effect of SAR443122 on the proportion of disease activity responders compared to placebo * Assess the effect of SAR443122 on the CLASI components score * Assess the effect of SAR443122 on the Investigator's global assessment for CLE (IGA-CLE) * Assess oral cavities for patients with oral lesions * Assess the disease specific quality of life (QoL) * Assess the safety and tolerability of SAR443122 in patients with CLE * Assess the pharmacokinetics (PK) exposure of SAR443122 in patients with CLE

Conditions

  • Cutaneous Lupus Erythematosus

Interventions

  • SAR443122Drug

    Pharmaceutical form: Capsule Route of administration: Oral

  • PlaceboDrug

    Pharmaceutical form: Capsule Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Cutaneous Erythematosus Disease Area and Severity Index - Activity (CLASI-A) Sub-Score at Week 12Time frame: Baseline (Day 1) and Week 12

Locations

50 sites in 15 countries. Site status is shown where the registry gives one.

  • GNP Research Site Number : 8400008

    Cooper City, Florida

  • DJL Clinical Research, PLLC Site Number : 8400003

    Charlotte, North Carolina

  • ClinOhio Research Services Site Number : 8400007

    Columbus, Ohio

  • Prolato Clinical Research Center Site Number : 8400010

    Houston, Texas

  • Investigational Site Number : 0320005

    Mendoza, Argentina

  • Investigational Site Number : 0320002

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0360001

    Camberwell, Victoria, Australia

  • Investigational Site Number : 0360002

    East Melbourne, Victoria, Australia

  • Investigational Site Number : 1240001

    London, Ontario, Canada

  • Investigational Site Number : 1240005

    Toronto, Ontario, Canada

  • Investigational Site Number : 1240002

    Sherbrooke, Quebec, Canada

  • Investigational Site Number : 1520009

    Valdivia, Los Ríos Region, Chile

  • Investigational Site Number : 1520006

    Osorno, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520007

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 2030002

    Brno, Czechia

  • Investigational Site Number : 2030004

    Náchod, Czechia

  • Investigational Site Number : 2030006

    Pardubice, Czechia

  • Investigational Site Number : 2030005

    Prague, Czechia

  • Investigational Site Number : 3480001

    Budapest, Hungary

  • Investigational Site Number : 3480002

    Szeged, Hungary

  • Investigational Site Number : 3560002

    Chandigarh, India

  • Investigational Site Number : 3560003

    Nagpur, India

  • Investigational Site Number : 3560004

    Nashik, India

  • Investigational Site Number : 3800001

    Genova, Italy

  • Investigational Site Number : 3800002

    Milan, Italy

  • Investigational Site Number : 4840003

    Benito Juárez, Mexico

  • Investigational Site Number : 4840004

    Chihuahua City, Mexico

  • Investigational Site Number : 4840001

    Monterrey, Nuevo León, Mexico

  • Investigational Site Number : 4840002

    Veracruz, Mexico

  • Investigational Site Number : 6160006

    Krakow, Lesser Poland Voivodeship, Poland

  • Investigational Site Number : 6160004

    Lublin, Lublin Voivodeship, Poland

  • Investigational Site Number : 6160007

    Katowice, Silesian Voivodeship, Poland

  • Investigational Site Number : 6430004

    Krasnodar, Russia

  • Investigational Site Number : 6430005

    Moscow, Russia

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.